Home » Newsletters » BioWorld

BioWorld

Nov. 5, 1991

View Archived Issues

SOMATIX GETS OPTIONS FOR CATHETER LICENSES

ECOGEN GETS EQUITY INVESTMENT

APPLIED BIOSCIENCE ACQUIRES PHARMACO

FDA APPROVES TRIALS OF PSORIASIS DRUG

IMMUNOGEN RETURNS TO OFFERINGS WELL

GENZYME GETS DIAGNOSTIC ENZYME BUSINESS

PET CANCER TREATMENT CONDITIONALLY APPROVED

IMMUNE TO FILE IND FOR ARTHRITIS VACCINE

GENTA FILES 'QUIET' IPO

BIOTECH BUBBLE MAY BE READY TO BURST

SPHINX INKS FOUR-YEAR DEAL WITH LILLY

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...